RPG Life Sciences, a part of RPG Enterprises, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT before exceptional items of 22% Y-o-Y and 18% Q-o-Q for Q2 FY25, maintaining the upward trajectory in EBITDA margins, which improved from 25.5% to 27.8% Y-o-Y.

Revenue from operations registered a growth of 12% Y-o-Y and a growth of 4% Q-o-Q at Rs 172.21 crores for Q2 FY25. For H1 FY25 too, the company posted a jump in PBT before exceptional items of 21% Y-o-Y and recorded EBITDA margin expansion from 24.3% to 26.5% Y-o-Y.

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25.

Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q2 FY25, the overall performance of the Company continued to be strong. Revenue and PBT before exceptional items grew by 12% and 22% respectively Y-o-Y. EBITDA margin retained its 5-year long upward trajectory growing from 25.5% to record 27.8% Y-o-Y. The Company continues to remain debt-free.

“Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market basis the five key initiatives - building some of our iconic “Textbook” brands like Naprosyn into megabrands through a comprehensive life cycle management program, shaping the successful products like Azoran into a multiproduct portfolio (Immunosuppressants) by leveraging our existing strong customer/brand franchise, building the futuristic portfolio of MABs into a formidable product segment through multi-branding strategy, replicating our smart and successful Rheumatology portfolio entry strategy to enter more specialties like Gastro and Derma, and deploying digital and productivity enhancement measures to ensure consistent salesforce productivity gains.

“We are now shaping our International Formulations and API businesses to emerge as second and third growth engines. For this to happen, while we are on course to modernize both our API and Formulations plants - by infusion of significant capex, our modernized R&D laboratories are also working to build a smart product pipeline. The International Formulations business is now registering healthy double-digit growth, and the API business is also showing promising growth.

“Our structural approach of cost optimization has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory. Cash that would be generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant will add to our existing cash surplus which we are actively working to deploy gainfully for business expansion.”